$TAUG Tauriga Sciences Inc. Increases Size of Init
Post# of 165
(Total Views: 408)
Posted On: 04/20/2021 11:38:11 AM
$TAUG Tauriga Sciences Inc. Increases Size of Initial Production Run for its Delta 8 THC Infused Tauri-Gum Version
https://finance.yahoo.com/news/tauriga-scienc...00880.html
This Initial Production Run has Been Doubled, Due to Strong Indications of Demand & Pre-Orders
NEW YORK, NY, April 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry, Evergreen Mint), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has doubled the initial production run total(s) for its Delta 8 Tetrahydrocannabinol (“Delta 8 THC”) infused version of Tauri-Gum™ (9thoverall product line SKU). This Tauri-Gum™ product version is infused with 10mg of Delta 8 THC (per each piece of chewing gum) and is manufactured in Evergreen Mint flavor – MSRP per Blister Pack is $18.99.
The Company is experiencing strong levels of performance and growth in its retail business. The Company has already generated record monthly sales (by a substantial margin), for the month of April 2021 (in just 20 days of this month). Driving the record performance in its retail business are the following factors: continued strength in E-Commerce business segment, Pre-Orders for its enhanced 25mg CBD/CBG infused versions of Tauri-Gum™, and Pre-Orders for its Delta 8 THC infused version of Tauri-Gum™. The Company’s previous monthly sales record of approximately $47,000, was established during July 2020.
Lastly, the Company continues to realize important and material progress, with respect to its ongoing Pharmaceutical Development initiative. This initiative refers to the Company’s ongoing development of its proposed, Cannabinoid based, Pharmaceutical grade “Anti-Nausea” chewing gum, targeting nausea that emanates from ongoing chemotherapy treatment. The Company expects to issue additional update(s) to shareholders within the near term.
https://finance.yahoo.com/news/tauriga-scienc...00880.html
This Initial Production Run has Been Doubled, Due to Strong Indications of Demand & Pre-Orders
NEW YORK, NY, April 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry, Evergreen Mint), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has doubled the initial production run total(s) for its Delta 8 Tetrahydrocannabinol (“Delta 8 THC”) infused version of Tauri-Gum™ (9thoverall product line SKU). This Tauri-Gum™ product version is infused with 10mg of Delta 8 THC (per each piece of chewing gum) and is manufactured in Evergreen Mint flavor – MSRP per Blister Pack is $18.99.
The Company is experiencing strong levels of performance and growth in its retail business. The Company has already generated record monthly sales (by a substantial margin), for the month of April 2021 (in just 20 days of this month). Driving the record performance in its retail business are the following factors: continued strength in E-Commerce business segment, Pre-Orders for its enhanced 25mg CBD/CBG infused versions of Tauri-Gum™, and Pre-Orders for its Delta 8 THC infused version of Tauri-Gum™. The Company’s previous monthly sales record of approximately $47,000, was established during July 2020.
Lastly, the Company continues to realize important and material progress, with respect to its ongoing Pharmaceutical Development initiative. This initiative refers to the Company’s ongoing development of its proposed, Cannabinoid based, Pharmaceutical grade “Anti-Nausea” chewing gum, targeting nausea that emanates from ongoing chemotherapy treatment. The Company expects to issue additional update(s) to shareholders within the near term.
(0)
(0)